• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday

    3/22/24 10:08:47 AM ET
    $ANNX
    $CGC
    $DAVE
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ANNX alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

    Shares of Worthington Steel, Inc. (NYSE:WS) rose sharply during Friday’s session as the company posted stronger-than-expected results for its third quarter.

    Worthington Steel posted adjusted earnings of 99 cents per share, beating market estimates of 84 cents per share. The company’s quarterly sales came in at $805.80 million, versus expectations of $700.50 million, according to data from Benzinga Pro.

    Worthington Steel shares jumped 18.8% to $37.92 on Friday.

    Here are some other big stocks recording gains in today’s session.

    • Murano Global Investments PLC (NASDAQ:MRNO) shares gained 147.5% to $23.94 after falling 46% on Thursday.
    • Summit Midstream Partners, LP (NYSE:SMLP) rose 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million.
    • Canopy Growth Corporation (NASDAQ:CGC) gained 18.6% to $5.41.
    • Annexon, Inc. (NASDAQ:ANNX) surged 17.3% to $7.14.
    • Ocugen, Inc. (NASDAQ:OCGN) rose 12.5% to $1.5090 after gaining 8% on Thursday. Ocugen recently appointed Huma Qamar, MD, MPH as Chief Medical Officer.
    • Lithium Americas (Argentina) Corp. (NYSE:LAAC) gained 12.2% to $5.77.
    • TScan Therapeutics, Inc. (NASDAQ:TCRX) rose 11.5% to $7.82.
    • Tilray Brands, Inc. (NASDAQ:TLRY) gained 11.2% to $2.1701.
    • Dianthus Therapeutics, Inc. (NASDAQ:DNTH) jumped 11% to $30.84 following upbeat results.
    • Dave Inc. (NASDAQ:DAVE) surged 11% to $41.08.
    • Astera Labs, Inc. (NASDAQ:ALAB) gained 9.6% to $70.30.
    • Clear Secure, Inc. (NYSE:YOU) climbed 8.4% to $20.46. CLEAR announced an increase to its share repurchase authorization and announced a special cash dividend of 32 cents.
    • FedEx Corporation (NYSE:FDX) climbed 7.9% to $285.78 after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion share repurchase program.
    • Immunome, Inc. (NASDAQ:IMNM) rose 7.8% to $26.02.
    • Sunnova Energy International Inc. (NYSE:NOVA) surged 5.5% to $5.99.
    • Foot Locker, Inc. (NYSE:FL) gained 5% to $24.85. Citigroup analyst Paul Lejuez upgraded Foot Locker from Sell to Neutral and announced a $24 price target.

     

    Now Read This: Top 3 Materials Stocks That Could Blast Off In Q1

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX
    $CGC
    $DAVE
    $DNTH

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    4/3/2026$10.00Neutral → Buy
    Roth Capital
    Tilray Brands Inc.
    $TLRY
    4/2/2026$10.00Neutral → Buy
    Roth Capital
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Worthington Steel Inc.
    $WS
    3/25/2026$46.00Overweight
    KeyBanc Capital Markets
    FedEx Corporation
    $FDX
    3/20/2026$360.00Reduce → Hold
    HSBC Securities
    FedEx Corporation
    $FDX
    3/20/2026$383.00 → $426.00Buy
    TD Cowen
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    More analyst ratings

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 188,500 shares of common stock to thirteen new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal

    4/2/26 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

    GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathies MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retino

    4/1/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year

    International Cannabis Accelerates with 73% Net Revenue Growth and 100% Increase in Cannabis Flower Sales Volume Year-Over-Year Canadian Adult-Use and Medical Cannabis Net Revenue Combined Increased 8% Year-Over-Year; Tilray Maintains #1 Cannabis Leadership Position in Canada by Revenue BrewDog Acquisition1 for ~£40 Million Cash Positions Tilray as a Global Craft Beverage Leader with Multi-Region Expansion Across Europe, Middle East, Australia, Asia-Pacific and the U.S. Strong Balance Sheet Supports Growth with $265 Million in Cash and Marketable Securities2 and ~$3.5 Million Net Cash NEW YORK and LONDON and LEAMINGTON, Ontario, April 01, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("

    4/1/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Higgins Jack

    4 - Immunome Inc. (0001472012) (Issuer)

    4/3/26 7:48:14 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rosett Max

    4 - Immunome Inc. (0001472012) (Issuer)

    4/3/26 7:46:52 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Zhang Junge

    4 - Ocugen, Inc. (0001372299) (Issuer)

    4/2/26 9:26:46 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    3/12/26 6:05:05 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bowsher Jon J bought $100,375 worth of shares (2,500 units at $40.15), increasing direct ownership by 16% to 17,893 units (SEC Form 4)

    4 - Worthington Steel, Inc. (0001968487) (Issuer)

    2/3/26 4:42:15 PM ET
    $WS
    Steel/Iron Ore
    Industrials

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/3/26 10:44:58 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/2/26 7:55:13 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ANNX
    $CGC
    $DAVE
    $DNTH
    SEC Filings

    View All

    SEC Form 8-K filed by TScan Therapeutics Inc.

    8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    4/2/26 7:30:07 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tilray Brands Inc.

    10-Q - Tilray Brands, Inc. (0001731348) (Filer)

    4/1/26 4:30:43 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    4/1/26 7:00:14 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Financials

    Live finance-specific insights

    View All

    Worthington Steel Reports Third Quarter Fiscal 2026 Results

    Worthington Steel, Inc. (NYSE:WS), a market-leading, value-added metals processing company, today reported financial results for the fiscal 2026 third quarter ended February 28, 2026. Third Quarter Highlights (all comparisons to the third quarter of fiscal 2025): Net sales of $769.8 million increased 12% compared to $687.4 million. Operating income of $3.1 million compared to $18.3 million. Net earnings attributable to controlling interest of $10.4 million compared to $13.8 million. Net earnings per diluted share attributable to controlling interest of $0.20 compared to $0.27; adjusted net earnings per diluted share attributable to controlling interest of $0.27 compared to $0.

    3/25/26 4:15:00 PM ET
    $WS
    Steel/Iron Ore
    Industrials

    Worthington Steel Declares Quarterly Dividend

    The board of directors of Worthington Steel, Inc. (NYSE:WS) has declared a quarterly dividend of $0.16 per common share. The dividend is payable on June 26, 2026, to shareholders of record at the close of business on June 12, 2026. Worthington Steel will host a conference call to discuss its fiscal 2026 third quarter results at 8:30 a.m. ET on Thursday, March 26, 2026. The conference call can be accessed by registering online at the link below. A live webcast of the call will be available through Events & Presentations in the Investors section of the Company's website at www.WorthingtonSteel.com and will be archived for one year. Live Conference Call Schedule Date: Thursday, M

    3/25/26 12:33:00 PM ET
    $WS
    Steel/Iron Ore
    Industrials

    Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026

    NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the third fiscal quarter which ended February 28, 2026, before the financial markets open on Wednesday, April 1, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Ti

    3/25/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ANNX
    $CGC
    $DAVE
    $DNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dianthus Therapeutics Inc.

    SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    12/3/24 9:19:18 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dianthus Therapeutics Inc.

    SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/22/24 4:41:50 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sunnova Energy International Inc.

    SC 13G - Sunnova Energy International Inc. (0001772695) (Subject)

    11/21/24 6:05:56 AM ET
    $NOVA
    Power Generation
    Utilities